Abstract

BackgroundThe Renal Health Program (RHP) was implemented in 2013 as a secondary prevention strategy to reduce the incidence of patients initiating dialysis and overall mortality. A previous study found that adherent patients have 58% protection against progression to dialysis compared to non-adherent. The main objective of the study was to estimate the lifetime economic and health consequences of the RHP intervention to determine its cost-effectiveness in comparison with usual care.MethodsWe use a Markov model of three health stages to simulate disease progression among chronic kidney disease patients in Lima, Peru. The simulation time-horizon was 30 years to capture the lifetime cost and health consequences comparing the RHP to usual care. Costs were estimated from the payer perspective using institutional data. Health outcomes included years lived free of dialysis (YL) and quality adjusted life years (QALY). We conducted a probabilistic sensitivity analysis (PSA) to assess the robustness of our estimates against parameter uncertainty.ResultsWe found that the RHP was dominant—cost-saving and more effective—compared to usual care. The RHP was 783USD cheaper than the standard of care and created 0.04 additional QALYs, per person. The Incremental Cost-Effectiveness Ratio (ICER) showed a cost per QALY gained of $21,660USD. In the PSA the RHP was dominant in 996 out of 1000 evaluated scenarios.ConclusionsThe RHP was cheaper than the standard of care and more effective due to a reduction in the incidence of patients progressing to dialysis, which is a very expensive treatment and many times inaccessible. We aim these results to help in the decision-making process of scaling-up and investment of similar strategies in Peru. Our results help to increase the evidence in Latin America where there is a lack of information in the long-term consequences of clinical-management-based prevention strategies for CKD patients.

Highlights

  • The prevalence of chronic kidney disease (CKD) in Lima, capital of Peru, is 21% [1]; 7% higher than the national mean [2]

  • We found that the event-free survival curve of the intervened cohort is constantly and slightly over the usual care (Fig. 2)

  • Indicating that the intervention produced gains in years lived without dialysis and quality adjusted life years (QALY)

Read more

Summary

Introduction

The prevalence of chronic kidney disease (CKD) in Lima, capital of Peru, is 21% [1]; 7% higher than the national mean [2]. Patients that progress to the end stage of the renal disease (ESRD) are likely to need renal replacement therapy (RRT). In Peru, Saldarriaga et al Cost Eff Resour Alloc (2021) 19:70 the most prevalent RRT option is hemodialysis [2], whose annual cost ranges from $3424 to $42,785 [4]. This cost can be prohibitive for many patients. The main objective of the study was to estimate the lifetime economic and health consequences of the RHP intervention to determine its cost-effective‐ ness in comparison with usual care

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call